Wugen, Inc.

ACTIVE

4260 Forest Park Ave Ste 100, Saint Louis, 密苏里州, United Stateswww.wugen.comHolding51–100 employeesEstablished: 2018-01-01

Clinical Trials

3 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2018

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

57.1%

Phase 2

14.3%

Trial Status Distribution

Active, not recruiting

28.6%

Completed

42.9%

Enrolling By Invitation

14.3%

Recruiting

14.3%

Clinical Trials

Trials sponsored by this organization (7)

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Phase 2

Recruiting

interventional

Jan 2025125 participants

A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Phase 1

Active, not recruiting

interventional

May 202430 participants

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Phase 1

Completed

interventional

Jul 20239 participants

Study of the Safety and Activity of WU-CART-007 in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

Phase 1

Active, not recruiting

interventional

Dec 202244 participants

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

Enrolling By Invitation

observational

Aug 202244 participants

A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

Phase 1

Completed

interventional

Jan 202228 participants

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Completed

interventional

4 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations